Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (January 2022)

48 slides from Curis's investor presentation, January 2022

  1. Slide 1: Corporate Presentation

    Corporate Presentation NASDAQ: CRIS

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”

  3. Slide 3: Corporate Overview

    Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $150M as of September 30, 2021; cash runway into 2024 CA-4948: first-in-class

  4. Slide 4: Pipeline

    Pipeline Curis develops novel, first-in-class cancer drugs PRE-CLINICAL CLINICAL MARKETED Dose Clinical Indication Proof of Principle Safety Optimization Activity Pivotal Commercial Two programs Heme Malignancies are the focus of this presentation CA-4948* IRAK4-driven Lymphoma IRAK4 (NHL, CLL, WM)

  5. Slide 5: IRAK4 Biology and CA-4948

    IRAK4 Biology and CA-4948

  6. Slide 6: IRAK4 Biology and CA-4948

    IRAK4 Biology and CA-4948 IRAK4 is a novel and important target across multiple heme malignancies IRAK4 in AML/MDS IRAK4 in B Cell Cancers Spliceosome mutation drives overexpression of IRAK4-L TLR Pathway is dependent upon IRAK4 for function (which causes constitutive activation of the myddosome) (t

  7. Slide 7: CA-4948 is the Leading IRAK4 Inhibitor in Development for Cancer

    CA-4948 is the Leading IRAK4 Inhibitor in Development for Cancer In Nov 2020, the NCI selected CA-4948, Curis’s Targeted design offers added potential benefit of also hitting FLT3 first-in-class IRAK4 inhibitor, and entered into an agreement (“CRADA”) with Curis to conduct both clinical and non-clin

  8. Slide 8: CA-4948 PK/PD

    CA-4948 PK/PD Attractive PK profile supports BID dosing and high target suppression Attractive PK Profile High Target Suppression • Half-life of ~6 hours Trough • Exposure at RP2D correlates with 98% inhibition Exposure Dose Inhibition • Supports BID dosing regimen 2.5μM 200mg 97% 4.1μM 300mg 98% 5.

  9. Slide 9: CA-4948 Preclinical Data

    CA-4948 Preclinical Data Clear anti-cancer activity suggests broad potential across heme malignancies AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Monotherapy & Combination p<0.05 100 vehicle Vehicle Mean Tumor Volume (mm3) ± SEM 1200 Relative Cell Growth % p<0.05 50 p<0.05 Ibrutinib CA-49

  10. Slide 10: CA-4948 Clinical Plan

    CA-4948 Clinical Plan Planned clinical studies for AML/MDS and B cell cancers AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Monotherapy & Combination Monotherapy No monotherapy studies planned Specific Subpopulations Broader Population 1) Patients with spliceosome mutation 1) R/R patients,

  11. Slide 11: CA-4948 in AML/MDS

    CA-4948 in AML/MDS

  12. Slide 12: CA-4948 in AML/MDS

    CA-4948 in AML/MDS Clinical studies designed to leverage the role of IRAK4/FLT3 in AML/MDS % of Patient Disease Driver Population IRAK4-L > 50%1 Rationale for Monotherapy FLT3 25-30%2 • IRAK4 / FLT3 is the largest targeted market in AML/MDS1,2 TET2 10-20%3 • Spliceosome mutation is a leading cause o

  13. Slide 13: CA-4948 in AML and MDS

    CA-4948 in AML and MDS Open-label, single arm, Phase 1/2 dose escalation and expansion study Dose Escalation: Dose Expansion: 200/300/400/500 mg BID 300 mg BID Study Objectives 1ᵒ: Determine maximum tolerated dose Determine recommended Phase 2 dose 2ᵒ: Pharmacokinetic (PK) profile 49 Total Patients

  14. Slide 14: Well-Tolerated and Manageable AE Profile for CA-4948 in AML/MDS

    Well-Tolerated and Manageable AE Profile for CA-4948 in AML/MDS with No Cumulative Toxicities Observed No Grade 4 or 5 TRAEs reported; all AEs were manageable Recommended Phase 2 Dose 200 mg BID 300 mg BID 400 mg BID 500 mg BID Grade 3+ Treatment-Related Adverse Event (N = 3) (N = 26) (N = 17) (N =

  15. Slide 15: Encouraging Clinical Activity in R/R AML/MDS Patient Populations

    Encouraging Clinical Activity in R/R AML/MDS Patient Populations CA-4948 shows activity as a monotherapy in patients with Spliceosome and FLT3 mutations Best Response Efficacy Population #1: AML Spliceosome Patients1 CR/CRh Rate 2/5 (40%) The CR and CRh patients CR 1/5 (20%) are both MRD-negative CR

  16. Slide 16: Clinical Data: R/R AML Patients with Spliceosome Mutation

    Clinical Data: R/R AML Patients with Spliceosome Mutation Patient Population #1 16

  17. Slide 17: Unmet Need for R/R AML Patients with Spliceosome Mutation

    Unmet Need for R/R AML Patients with Spliceosome Mutation No approved targeted therapies and no unified standard of care for these patients Elderly / Intensive Non-Intensive • Spliceosome mutations occur in ~10% of AML patients1 Induction Ven/HMA - These mutations create a chronic inflammatory marro

  18. Slide 18: Initial CA-4948 Data Compare Favorably to Existing Therapies

    Initial CA-4948 Data Compare Favorably to Existing Therapies Potential to meaningfully improve outcomes in R/R AML patients with spliceosome mutation Most Commonly Used in R/R AML with Wild Type FLT3/IDH1 Gemtuzumab CA-4948 Decitabine2,3 Azacitidine2,4 LoDAC5 Ozogamicin2,6 Monoclonal Anti-CD33 IRAK4

  19. Slide 19: Encouraging Clinical Activity in R/R AML Patients with Spliceosome Mutation

    Encouraging Clinical Activity in R/R AML Patients with Spliceosome Mutation Achieved 40% CR/CRh rate, with treatment duration >6 months to date in responding patients Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx Risk Category CA-4948 % Change (BID) Mutations Baseline Res

  20. Slide 20: Clinical Data: R/R MDS Patients with Spliceosome Mutation

    Clinical Data: R/R MDS Patients with Spliceosome Mutation Patient Population #2 20

  21. Slide 21: Spliceosome Mutations Common in MDS

    Spliceosome Mutations Common in MDS Large unmet need for R/R MDS patients with spliceosome mutation SCT Eligible Not SCT Eligible • Spliceosome mutations (U2AF1/SF3B1) are the most prominent mutations HMA HMA in MDS, accounting for ~30% of all MDS patients1 - These mutations create a chronic inflamm

  22. Slide 22: Clear Unmet Need in Relapsed/Refractory MDS

    Clear Unmet Need in Relapsed/Refractory MDS Current standard of care offers little therapeutic benefit to patients Most Commonly Used Therapies in R/R MDS1 CA-4948 Chemotherapy2 Decitabine3 Azacitidine3 IRAK4 Inhibitor Chemotherapy HMA HMA • 57% mCR rate • ~8% ORR • 2nd line response data • 2nd line

  23. Slide 23: Encouraging Clinical Activity in R/R MDS Patients with Spliceosome Mutation

    Encouraging Clinical Activity in R/R MDS Patients with Spliceosome Mutation Marrow blast reduction achieved in 5 of 7 patients, including 4 marrow CRs Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx IPSS-R CA-4948 % Change (BID) Mutations Baseline Response # Lines Therapy (

  24. Slide 24: Clinical Data: R/R AML Patients with FLT3 Mutation

    Clinical Data: R/R AML Patients with FLT3 Mutation Patient Population #3 24

  25. Slide 25: IRAK4 Signaling Drives Resistance to FLT3 Inhibitors

    IRAK4 Signaling Drives Resistance to FLT3 Inhibitors IRAK4 inhibition is synergistic with, and prevents adaptive resistance to, FLT3 inhibition • IRAK4 activity increases after • IRAK and FLT3 inhibition is synergistically cytotoxic • Mice die if treated with quizartinib, but survive quizartinib tre

  26. Slide 26: CA-4948 May Address Unmet Need in R/R AML Patients with FLT3 Mutation

    CA-4948 May Address Unmet Need in R/R AML Patients with FLT3 Mutation No approved therapies for patients R/R to FLT3 inhibitors Most Commonly Used Therapies in R/R AML Patients with FLT3 Mutation1 Gemtuzumab CA-4948 Gilteritinib2,3 Azacitidine2 Decitabine2 Ozogamicin2,4 Monoclonal Anti-CD33 ~30% of

  27. Slide 27: Encouraging Clinical Activity in R/R AML Patients with FLT3 Mutation

    Encouraging Clinical Activity in R/R AML Patients with FLT3 Mutation Achieving disease modification in heavily pretreated patients with CA-4948 monotherapy Risk Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx Category CA-4948 % Change (BID) Mutations Baseline Response (ELN)

  28. Slide 28: CA-4948 Has Potential to Address Clear Unmet Need in AML and MDS

    CA-4948 Has Potential to Address Clear Unmet Need in AML and MDS First-in-class IRAK4 inhibitor targets specific genetic populations in AML and MDS CA-4948 addresses a novel target (IRAK4) and: (1) demonstrates clear anti-cancer activity as an oral single agent Next Steps in Expansion (2) is active

  29. Slide 29: CA-4948 in B Cell Cancers

    CA-4948 in B Cell Cancers

  30. Slide 30: CA-4948 in B Cell Cancers

    CA-4948 in B Cell Cancers Monotherapy Phase 1/2 study design and patient characteristics Heavily pre-treated population Study Objectives Baseline Patient Characteristics Patients (n=31) 1ᵒ: Determine maximum tolerated dose Female n (%) : Male n (%) 26 (84) : 5 (16) Determine recommended Phase 2 dose

  31. Slide 31: CA-4948 in B Cell Cancers: Two Potential Biomarkers

    CA-4948 in B Cell Cancers Two potential biomarkers may increase probability of success NF-κB phospho-p50 positive expression of p-p50 indicates the NF-κB complex is active BCR Pathway TLR Pathway Baseline testing may support future patient selection B cell TLR1 TLR2 Patient Best Patient Best TLR4 TL

  32. Slide 32: CA-4948 in B Cell Cancers: Safety Data

    CA-4948 in B Cell Cancers Promising preliminary safety data 200 mg BID 300 mg BID 400 mg BID All (n=5); (%) (n=6); (%) (n=8); (%) (n=30); (%) Adverse Reaction Predictable and manageable safety profile All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades Grade 3 or 4 All Grades Diarrhea 20 0 33

  33. Slide 33: CA-4948 in B Cell Cancers: Best Response

    CA-4948 in B Cell Cancers Preliminary clinical data: clear reduction in tumor burden Change in Tumor Burden for 13 Evaluable Patients Dose Response Observed in WM Patient (200mg BID+) (50mg - 300mg BID) 50% Clear Single Agent Anti-Cancer Activity at RP2D Clear Single Agent Anti-Cancer Activity • Tum

  34. Slide 34: CA-4948 in B Cell Cancers: Durability Profile

    CA-4948 in B Cell Cancers Preliminary clinical data: strong durability profile Patients Dosed at Recommended Ph2 Dose (300mg BID) Strong Durability Profile at RP2D Patients have remained on therapy 1-2 years dotted line indicates ongoing treatment Data cut-off: 23Nov2020 Days on Study 34

  35. Slide 35: CA-4948 in B Cell Cancers: Combine with BTKi

    CA-4948 in B Cell Cancers CA-4948 is the ideal candidate to combine with BTKi to maximize downregulation of NF-κB Next Steps in Expansion • Patients are treated with BTKi because downregulating • BTKi naïve, Marginal Zone Lymphoma (MZL) NF-κB activity provides benefit in B Cell Cancers • BTKi naïve,

  36. Slide 36: VISTA Biology and CI-8993

    VISTA Biology and CI-8993

  37. Slide 37: Anti-cancer Mechanisms of Checkpoint Inhibitors

    Anti-cancer Mechanisms of Checkpoint Inhibitors Role of VISTA may go beyond other checkpoint inhibitors We believe VISTA inhibition has potential for broad application in many tumor types in monotherapy and in combination with existing checkpoint inhibitors Target Checkpoint Inhibitors Approved in M

  38. Slide 38: CI-8993 Preclinical Data

    CI-8993 Preclinical Data Clear anti-cancer activity suggest potential transformation of immune-oncology treatment Monotherapy Combination Therapy Anti-VISTA inhibited tumor growth Anti-VISTA inhibited xenograft growth in B16ova melanoma model1 in checkpoint resistant CT26 model2 Control n=14 100% Da

  39. Slide 39: Incorporated Learnings from CI-8993 Prior Clinical Study

    Incorporated Learnings from CI-8993 Prior Clinical Study Pharmacodynamic activity (cytokine release) observed in initial clinical study CI-8993 is the first anti-VISTA monoclonal antibody (IgG1κ) to be studied in clinical trials • Janssen initiated a Ph1 study in 2016 and enrolled 12 patients1 - Tra

  40. Slide 40: CI-8993 Clinical Plan: Phase 1 Dose Escalation Study

    CI-8993 Clinical Plan: Phase 1 Dose Escalation Study On-going clinical study to determine safety Patient Population • Patients with advanced refractory solid tumors Phase 1 Dose Escalation Study Design (includes mesothelioma, melanoma, NSCLC, TNBC) Treatment Continue dose escalation • Bi-weekly dosi

  41. Slide 41: CI-8993 Has Demonstrated Favorable Safety Profile

    CI-8993 Has Demonstrated Favorable Safety Profile Successfully managed expected CRS at all levels dosed to date All Grades 0.15 mg/kg 0.3 mg/kg Grade 3+ 0.15 mg/kg 0.3 mg/kg Treatment-Related Adverse Events (N = 7) (N = 5) Treatment-Related Adverse Events (N = 7) (N = 5) Occurring in 2+ Patients n (

  42. Slide 42: CI-8993 Has Demonstrated Favorable PK Profile

    CI-8993 Has Demonstrated Favorable PK Profile CI-8993 mean plasma concentration vs. time profile following IV administration at full dose Plasma Concentration Cmax Levels 1,000,000 1,000,000 (ng/mL) Mean 0.15 mpk DAY 1 Concentration(ng/mL) Mean 0.15 mpk DAY 29 78.4-fold Mean 0.3 mpk DAY 1 100,000 10

  43. Slide 43: Pharmacodynamic Effects of CI-8993 in Patients

    Pharmacodynamic Effects of CI-8993 in Patients CI-8993 affects multiple anticancer mechanisms supporting VISTA potential Decreased recruitment of MDSCs NK Cell Activation 1 2 Decreased CXCR2 on granulocytes Decreased CD16 on NK cells CI-8993 reduces MDSCs Cohort 1 Cohort 2 Cohort 1 Cohort 2 CI-8993

  44. Slide 44: Pharmacodynamic Effects of CI-8993 in Patients

    Pharmacodynamic Effects of CI-8993 in Patients CI-8993 affects multiple anticancer mechanisms supporting VISTA potential Enhanced Antigen Presentation Release of T-Cell Activating Factors 4 5 Increased HLA-DR on Monocytes Increased Secretion of IP10 CI-8993 enhances antigen Cohort 1 Cohort 2 Cohort

  45. Slide 45: CI-8993 Cleared Initial Safety Hurdle

    CI-8993 Cleared Initial Safety Hurdle First-in-class CI-8993 has potential for broad applicability in immune checkpoint therapy • Encouraging initial safety data appears to demonstrate Next Steps in Dose Escalation effectiveness of procedures implemented to manage expected CRS • Continue dose-escala

  46. Slide 46: Corporate Overview

    Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $150M as of September 30, 2021; cash runway into 2024 CA-4948: first-in-class

  47. Slide 47: Committed, Experienced Leadership Team

    Curis Committed, Experienced Leadership Team Rachel Blasbalg James Dentzer Christine Guertin Robert Martell Head, Human Resources President & CEO Head, Regulatory Head, R&D Mark Noel Reinhard von Roemeling Raul Soikes Nancy Soohoo William Steinkrauss Head, Intellectual Property Head, Clinical Develo

  48. Slide 48: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

Curis — Investor Presentation (January 2022) on 6ix